Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03389802 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
A Phase 1 study of Glioblastoma Multiforme and Medulloblastoma, sponsored by Pediatric Brain Tumor Consortium.
- Active
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 11
- Study locations
NCT03389802: Active Phase 1 study of Glioblastoma Multiforme and Medulloblastoma, sponsored by Pediatric Brain Tumor Consortium.
NCT03389802 is a Phase 1 study of Glioblastoma Multiforme and Medulloblastoma that is active but no longer recruiting, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 32 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (67% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03389802, a Phase 1 study of Glioblastoma Multiforme and Medulloblastoma, is active but no longer recruiting, sponsored by Pediatric Brain Tumor Consortium.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 11
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed diffuse intrinsic pontine glioma. APX005M can trigger activation of B cells, monocytes, and dendritic cells and stimulate cytokine release from lymphocytes and monocytes. APX005M can mediate a direct cytotoxic effect on CD40+ tumor cells.
Primary Outcome
DLTs were defined as adverse events (AE) at least possibly attributed to APX005M that occurred during the first 2 courses (6 weeks) following APX005M administration. DLTs included any APX005M-related AE that led to dose reduction or permanent cessation of therapy or resulted in a treatment delay \>2 weeks. Hematologic DLTs included grade 3 neutropenia with fever, any grade 4 hematologic toxicity except lymphopenia, and grade 3 thrombocytopenia on 2 separate days or requiring platelet transfusion
Conditions Studied
Interventions
- BIOLOGICAL APX005M treatment for recurrent or refractory primary malignant CNS tumor patients
- BIOLOGICAL APX005M treatment for newly diagnosed DIPG patients
Study Locations (11)
California
- Children's Hospital Los Angeles - Los Angeles
- Lucile Packard Children Hospital Stanford University - Palo Alto
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Childrens National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Atlanta
Illinois
- Lurie Childrens Hospital-Chicago - Chicago
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cincinnati Children Hospital Medical Center - Cincinnati
Pennsylvania
- Children Hospital of Pittsburgh of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
What the registry record for NCT03389802 still lists
NCT03389802 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (67% lower).
The record links to 6 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 2 interventions - of which APX005M treatment for recurrent or refractory primary malignant CNS tumor patients is the first listed.
NCT03389802 lists 11 locations in 10 states (California, Colorado, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT03389802 about?
NCT03389802 is a clinical study titled "Phase I Study of APX005M in Pediatric Central Nervous System Tumors". This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed diffuse intrinsic pontine glioma. APX005M can trigger activation of B c...
What is the current status of trial NCT03389802?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-03-01. Estimated completion is 2026-06-30.
What conditions does trial NCT03389802 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Medulloblastoma, Diffuse Intrinsic Pontine Gliomas (DIPG), High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS).
What interventions are being tested in trial NCT03389802?
The interventions under investigation include: APX005M treatment for recurrent or refractory primary malignant CNS tumor patients (BIOLOGICAL), APX005M treatment for newly diagnosed DIPG patients (BIOLOGICAL).
Who is sponsoring clinical trial NCT03389802?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03389802 being conducted?
This trial has 11 study locations across California, Colorado, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03389802's enrollment target sits among peer trials
32 58th of 88 higher than 29 of 88 other Glioblastoma Multiforme trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI